Valitacell and Solentim announce collaboration to accelerate discovery and development of biologic drugs and advanced cell therapies

Dublin, Ireland and Bournemouth, UK, 21st February 2019 / Sciad Newswire / Valitacell, a biotechnology company transforming cell-based manufacturing, and Solentim, a global leader in cell line development instrumentation, today announce a new collaboration to enable earlier identification of biological candidates and to accelerate the development of breakthrough medicines.

Valitacell’s novel in-line analytical profiling technologies and its data driven/machine learning approach, together with Solentim’s innovative image-driven liquid handling and cell measurement technology, will transform current workflows, creating a streamlined, automated platform which synergises precise cell manipulations, attribute-rich profiling of clones and earlier decision making.

“This collaboration combines our expertise in both biotherapeutics and emergent cellular therapy, and will optimise the process of drug discovery. We look forward to working in partnership with Solentim as we continue to discover and develop life-saving medicines that improve patients’ lives” said Dr Terry McWade, CEO of Valitacell.

Dr Ian Taylor, Chief Commercial Officer of Solentim, added, “We are delighted to be collaborating with Valitacell – this combination of technologies will provide a further component to our unique integrated solution for accelerating stable cell line development workflows. It will provide significant benefits for richer clone information and earlier decision-making on the best candidates to progress.”

Further details of the collaboration will be announced in the coming weeks.

Ends

For further information, contact:

Corporate Contacts:

Valitacell Ltd
Carolanne Doherty, Sales & Marketing manager
T: +353 860630395
E: Carolanne.doherty@valitacell.com

Solentim Ltd
Ian Taylor, Chief Commercial Officer
T: +44 (0)1202 051813
E: ian.taylor@solentim.com

PR Contact:
Emma Pickup / Juliette Craggs
Sciad Communications Ltd
T: +44 (0)20 7470 8801
E: solentim@sciad.com

Notes to Editors

About Valitacell

Valitacell is an Ireland-based biotechnology company accelerating the development of life-saving medicines with a suite of novel, intelligent analytical technology platforms, engineered to provide process control in cell-based manufacturing to achieve the highest levels of bioprocess performance. In 2016 Valitacell was the overall winner of the InterTrade Ireland Seedcorn Award. Visit www.valitacell.com for more information.

About Solentim

Solentim enables its life science industry customers to develop a greater number of more effective pharmaceuticals to help patients live healthier, for longer. It does this through designing and manufacturing highly innovative instruments that facilitate the process of commercial cell line development. This phase of biopharmaceutical production is a high-value process which is intrinsically expensive and time-consuming. Solentim’s solutions significantly shorten the upstream cell line development workflow process and therefore make drug production faster and more cost effective. It’s products, Cell Metric^® and VIPS™, represent the next generation of single cell printing and provide documented proof of monoclonality for the FDA and other regulatory bodies. All of the world’s top ten pharmaceutical companies use Solentim products. Established in 2010 and with global headquarters in Dorset, UK; the organisation employs over 40 people across the UK, Europe, Asia and the USA. In 2018, Solentim was the recipient of two highly prestigious Queen’s Awards and was also a winner in the Deloitte UK Technology Fast 50. Visit www.solentim.com for more information.